GenSci’s Growth Hormone Project (Phase II) Enters Stage of Equipment Testing

Updated : 2019-05-14Source : CCFAO
【Fonts: A+ A A- Print

The construction of the plant totaling 80,000 square meters for the project Growth Hormone (Phase II) of the GenSci Pharmaceuticals Co., Ltd. (GenSci) was completed, and all the relevant production equipment was said to have entered the stage of testing.

The project growth hormone (Phase II) covers a land area of 7,200 square meters, and a construction area of 84,000 square meters for which more than RMB1 billion has been invested. After the project goes operational, the production capacity of GenSci will be expanded by five times, making GenSci the largest restructured human growth hormone producer in the world with an annual production capacity of 30 million which is expected to bring about RMB 10 billion sales revenues and RMB4 billion profits and taxes.

Over the past 20 plus years, GenSci has been focusing on market expansion and product sale on one hand and meanwhile on productivity reserve as well as product research and development on the other, which in turn has brought about stable sales revenues, profits and taxes. The construction of the project (Phase II) is of great significance for GenSci to maintain a leading position in market, expanding market shares and securing RMB10 billion sales revenues in the forthcoming 3 to 5 years for its three pillar products highlighting “Height Propeller”, “Reproduction” and “Anti-aging”.